ant01 in the prevention of alzheimer
play

Erik BUNTINX , MD-Psychiatrist Founding CEO erik.buntinx@aneurotech.com 1 www.aneurotech.com ANT01 in the Prevention of Alzheimer EXECUTIVE SUMMARY IN PRECLINCAL STAGE OF ALZHEIMER DISEASE (AD), ANT01 IS AIMED TO INDUCE COGNITIVE ENHANCEMENT

0 downloads 1 Views 550 KB Size Report
  1. Erik BUNTINX , MD-Psychiatrist Founding CEO erik.buntinx@aneurotech.com 1 www.aneurotech.com

  2. ANT01 in the Prevention of Alzheimer EXECUTIVE SUMMARY IN PRECLINCAL STAGE OF ALZHEIMER DISEASE (AD), ANT01 IS AIMED TO INDUCE COGNITIVE ENHANCEMENT IN PATIENTS WITH MAJOR DEPRESSIVE DISORDER ➢ Driven by ANT01’ unique selective modulation of 5 -HT2A and D4 receptors ➢ With Initial Clinical POP (Proof-Of-Principle) Bio-Marker Data in Targeted Patients, validated by the KoL of the UK Dementia Research Institute, Prof. Dr. Bart De Strooper ➢ Making ANT01 an unique opportunity in the competitive field of AD drug development and as such receiving from two of the top 5 global pharmaceutical companies (with a yearly revenue greater than 50 B USD) a formal request to review the positive proof-of-concept data once they are achieved. As a result, ANT is currently in the process of initiating its Proof of Concept Study RESTORE-COG 2

  3. ANT’ KEY TEAM Founding CEO In Inventor Erik Buntinx , M.D. , Founding CEO Medical Chair ir Scie ientific Center Anima & Anima Research Center, Alken (BE) Advis isory ry Board Experienced Chief Executive ▪ Officer with a demonstrated Charles B. Nemeroff , M.D., Ph.D., Dell Med, UT, history of working in the Austin(US), Mulva Clinic for the Neurosciences. pharmaceuticals industry. Inventor of multiple President of the Anxiety and Depression Association of ▪ ▪ worldwide granted patents America (ADAA). in the field of neurosciences Co-editor in chief (with Alan F. Schatzberg, M.D.) ▪ Veteran Principle ▪ of the Textbook of Psychopharmacology Investigator in key CNS Co-editor in chief of Personalized Medicine in Psychiatry. ▪ programs

  4. ANT01 in the Prevention of Alzheimer CURRENT ALZHEIMERS’ OUTLOOK: IN PRECLINCAL STAGE OF AD ANY KNOWN POC STUDY ADRESSING COGNITIVE ENHANCEMENT 4

  5. ANT01 in the Prevention of Alzheimer UNIQUE DIFFRERENTIATING POSITION FROM COMPETITORS IN AD: AN ESTABLISCHED PHASE II, SYSTEM-REDUCING SMALL MOLECULE IN PRECLINICAL STAGE OF AD 5

  6. ANT01 in the Prevention of Alzheimer RISK TO DEVELOP ALZHEIMER DISEASE (AD) Higly Correlated with co-morbidity DEPRESSION & SUBJECTIVE COGNITIVE DECLINE (SCD – Mean MMSE (SD): 27,5 (2,2))* ANT01 Phenotype Preclinical Alzheimer Disease Patients with Major Depressive Disorder Kaplan-Meier curve reflecting the risk of mild cognitivie impairment and dementia across the different combinations of presentation (n=13,462). MCI: Mild Cognitive Impairment; SCD: subjective cognitive decline * Liew et al. Alzheimer’s Research & Therapy (2019) 11: 170 & Simona et al, Journal of Alzheimer’s Disease 66 (2018) 483-495

  7. ANT01 in the Prevention of Alzheimer ANT01 Endo-Phenotype in Alzheimer: HIPPOCAMPAL SYNAPSE LOSS, correlated with Increased tau-deposition and cognitive decline* * Van Laere Koen et al, KULeuven 7

  8. ANT01 in the Prevention of Alzheimer ANT01 Endo-Phenotype in Alzheimer: MODULATION OF HIPPOCAMPAL SYNAPSES AD Target Brain Area Hippocampus where post-synaptic Dopamine 4 Receptor - Modulation entrains gamma frequency, attenuating amyloid load and modifying microglia - Activation suppresses long term potentiation which is impaired in AD Need for modulation of the negative impact of D4 receptor dependent dopaminergic activation of hippocampal synapses on cognitive performance * Iaccarino H.F. et al , Nature (2016) 540: 230 ** Andersson R.H. et al , PNAS (2012) 109: 13118

  9. ANT01 Proof-of-Principle Bio-marker Study (n=3) ANT01 induces Alzheimer Patient – in contrast with AD patients – 3 weeks 3 months 1.5 30 rel gamma (abs. values) Relative gamma power 25 MMSE Total Score Sustained Enhanced Cognitive AD Stage (Total Score) (abs. values) 1.0 20 MMSE 15 Performance over 6 months 0.5 10 5 in defined AD at risk patients 0.0 0 pre-Rx post-Rx pre-AD Stage accompagnied by enhanced REM Sleep Associated Frontal Gamma Frequency At Risk Patient 1 At Risk Patient 2 >6 months 3 weeks >6 months 3 weeks 1.5 30 1.5 30 rel gamma (abs. values) Relative gamma power rel gamma (abs. values) Relative gamma power 25 MMSE Total Score 25 MMSE Total Score (Total Score) (abs. values) (Total Score) 1.0 20 (abs. values) 1.0 20 MMSE MMSE 15 15 0.5 10 0.5 10 5 5 0.0 0 0.0 0 pre-Rx post-Rx pre-Rx post-Rx

  10. ANT01 in the Prevention of Alzheimer: A Potential +10 B Drug US POPULATION 2017 2017 325.700.000 MDD PREVALENTION 4% 13.028.000 MDD HISTORY + SUBJECTIVE COGNITIVE DECLINE 30% 3.908.400 WITH ACUTE Rx 50% 1.954.200 TOTAL PATIENTS TREATED PER YEAR WITH INITIAL RESPONSE 60% 1.172.520 AD PREVALENTION* 2030 8.400.000 TOTAL HEALTHCARE COST AD* 2030 $ 449.400.000.000 COST AD PATIENT PER YEAR* 2030 $ 53.500 NEW CASES PER YEAR* 2030 615.000 COST NEW CASES PER YEAR 2030 $ 32.902.500.000 PART NEW CASES AD IN TOTAL COST AD 2030 7,32% PROJECTED TOTAL COST AD +10 YEARS* 2040 $ 868.800.000.000 ADDITIONAL COST AD +10 YEARS 2040 $ 419.400.000.000 PART NEW CASES AD IN TOTAL COST AD +5 YEARS 2035 37% COST NEW CASES AD +5 YEARS 2035 $ 318.042.857.143 PREVENTION OF AD WITH ANT01 TOTAL OF NEW CASES AD PREVENTED WITH ANT01 PER YEAR 20% 234.504 SAVING HC COST AD +5 YEARS WITHOUT COST DRUG Rx 2035 $ 63.608.571.429 COST DRUG Rx PER YEAR 20% $ 12.721.714.286 TREATMENT COST PER MONTH PER PATIENT 12 $ 904 NET SAVING HEALTHCARE COST PER YEAR 2035 $ 50.886.857.143 *Alzheimer’s Association (2018) Alzheimer’s Disease Facts and Figures. Alzheimers Dement 14: 367 10

Recommend Documents


alzheimer bulgaria association 2011 2016
Alzheimer Bulgaria Association 2011 -

Alzheimer Bulgaria Association 2011 - 2016 Dublin, 7 th of November About

the challenge of dementia prospects for prevention
The Challenge of Dementia: Prospects

The Challenge of Dementia: Prospects for Prevention A 100 year journey from

caring for a loved one with
Caring for a Loved One with

Caring for a Loved One with Alzheimer's Disease Peggy Higgins Emeritus

novel regulatory science research on drugs for alzheimer
Novel Regulatory Science Research on

EMA 24 November, 2014 Workshop on Alzheimer's disease Novel Regulatory

developing and implementing provincial alzheimer
Developing and implementing provincial

Developing and implementing provincial Alzheimer Strategies Lessons learned

the choice of outcome parameters and need for distinct
The choice of outcome parameters and

The choice of outcome parameters and need for distinct assessment tools with

alzheimer s disease infectious type
Alzheimer s Disease, Infectious type

Alzheimer s Disease, Infectious type Evidence from Harvard Brain Bank Cases

the place for treatments of associated neuropsychiatric
The Place for Treatments of Associated

The Place for Treatments of Associated Neuropsychiatric and Other Symptoms in

multifunctional diamine age ale inhibitors with promising
Multifunctional diamine AGE/ALE

Multifunctional diamine AGE/ALE inhibitors with promising properties for

understanding alzheimer disease s structural connectivity
Understanding Alzheimer diseases

Understanding Alzheimer diseases structural connectivity through explainable

ucsf memory and aging center 2016
UCSF Memory and Aging Center 2016 Best

UCSF Memory and Aging Center 2016 Best Practices in Mild Cognitive Impairment

4 applications in computational biology
4. Applications in Computational

4. Applications in Computational Biology Karsten Borgwardt Department

ada case law update
ADA Case Law Update JO Y C E W A L K

8/22/2015 ADA Case Law Update JO Y C E W A L K ER - JO N ES SEN IO R A T T

time preferences health behaviors and energy consumption
TIME PREFERENCES, HEALTH BEHAVIORS,

TIME PREFERENCES, HEALTH BEHAVIORS, AND ENERGY CONSUMPTION David Bradford,

ethical issues in international ethical issues in
Ethical issues in international

Ethical issues in international Ethical issues in international collaborative

the biology of amphibians
The Biology of Amphibians Agnes

The Biology of Amphibians Agnes Scott College Mark Mandica Executive

workshop on the role of speech in developing robust
Workshop on the Role of Speech in

Workshop on the Role of Speech in Developing Robust Speech Processing

machine learning algorithms for neuroimaging based
Machine Learning Algorithms for

Machine Learning Algorithms for Neuroimaging-based Clinical Trials in

high value care supporting
High Value Care: Supporting the Family

High Value Care: Supporting the Family Caregiver Workforce Jennifer L. Wolff,

probabilistic modelling and reasoning introduction
Probabilistic Modelling and Reasoning

Probabilistic Modelling and Reasoning Introduction Michael Gutmann

models for time to event data
Models for time-to-event data From

Models for time-to-event data From Coxs proportional hazards model to deep

the intelligent habitat and everyday life activity support
The intelligent habitat and everyday

The intelligent habitat and everyday life activity support Hlne Pigot, Andr